Riskpilot← Back to searchSign inGet full accessETVAX AB
ABActiveOrg 5567973143Industrivägen 1 4trResearch and experimental development on natural sciences and engineering · NACE 7210Est. 200927 employees
Revenue 2024
SEK 5,5M
+11% vs 2023
EBITDA margin
-481.0%
+12% vs 2023
Equity ratio
19.8%
Financial strength
Net profit 2024
SEK 15K
-44% vs 2023
| Revenue | SEK 5,5M | +11% |
| EBITDA | SEK -26,6M | +12% |
| Net profit | SEK 15K | -44% |
| Total assets | SEK 30,5M | +1% |
| Equity | SEK 6,1M | +0% |
| Employees | 27 | — |
Legal name
ETVAX AB
Org number
5567973143
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
16 december 2009
Share capital
SEK 100 000
Employees
27 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firmanbeträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska bedriva forskning, utveckling och tillverkning av medicinska, kemiska och biotekniska produkter och därmed förenlig verksamhet.
Address
Industrivägen 1 4tr
Phone
+46727125120
Email
bjorn@etvax.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 5 344 | 5 360 | 6 853 | 5 000 | 3 000 | 5 000 | 5 000 | 5 527 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −7 887 | −7 818 | −9 305 | −14 847 | −15 140 | −14 417 | −20 640 | −31 240 | −30 263 | −26 586 |
| Depreciation & amort. | −284 | −323 | −1 169 | −1 376 | −1 089 | −751 | −698 | −360 | −398 | −530 |
| EBIT | −8 171 | −8 141 | −10 474 | −16 223 | −16 229 | −15 168 | −21 338 | −31 600 | −30 661 | −27 116 |
| Net financials | −1 | — | — | 9 | −1 | −1 | −2 | 18 | 121 | 144 |
| Profit before tax | 869 | 12 | 209 | 16 | 17 | 12 | 23 | 17 | 51 | 29 |
| Tax | −0 | −0 | −3 | −15 | −15 | −8 | −12 | −7 | −24 | −14 |
| Net profit | 869 | 12 | 206 | 1 | 2 | 4 | 11 | 10 | 27 | 15 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 11 456 | 10 345 | 22 250 | 15 215 | 15 299 | 21 671 | 26 628 | 18 886 | 30 377 | 30 541 |
| Equity | 5 767 | 5 780 | 5 986 | 5 988 | 5 989 | 5 993 | 6 004 | 6 014 | 6 042 | 6 057 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 5 689 | 4 565 | 16 264 | 9 227 | 9 309 | 15 678 | 20 624 | 12 872 | 24 336 | 24 484 |
| Total debt | 5 689 | 4 565 | 16 264 | 9 227 | 9 309 | 15 678 | 20 624 | 12 872 | 24 336 | 24 484 |
EBITDA margin
-481.0%
This company
15.8%
Market median
-3144% vs market
20152024
Equity ratio
19.8%
This company
38.2%
Market median
-48% vs market
20152024
Return on equity
0.2%
This company
18.4%
Market median
-99% vs market
20152024
Net profit margin
0.3%
This company
8.1%
Market median
-96% vs market
20152024
Asset turnover
0.18×
This company
1.12×
Market median
-84% vs market
20152024
Debt / equity
4.04×
This company
0.62×
Market median
-552% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AM Chief Auditor | Chief Auditor | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Scandinavian Biopharma Holding AB | Company | 100.0% | 100.0% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Scandinavian Biopharma Holding AB
ETVAX AB Board members of ETVAX AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anna Maria Wretholm | Chief Auditor | 0 companies |
| Björn Magnus Sjöstrand | Chairman | 0 companies |
| Ingrid Anette Elmqvist | Board of Directors | 0 companies |
| Nils Ivar Arne Carlin | Board of Directors | 0 companies |